ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
AstraZeneca PLC

AstraZeneca PLC (AZN)

70,76
-0,48
(-0,67%)
Fermé 01 Février 10:00PM
70,0818
-0,6782
(-0,96%)
Après les heures de négociation: 1:55AM

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
70,0818
Prix Achat
70,50
Prix Vente
71,30
Volume échangé
3 697 506
70,49 Fourchette du Jour 71,55
0,00 Plage de 52 semaines 0,00
Cap du marché
Clôture Veille
71,24
Ouverture
70,64
Dernière Transaction
10
@
70.77
Dernière heure de transaction
Volume financier
US$ 262 319 852
VWAP
70,9451
Volume moyen (3 m)
-
Actions en circulation
3 101 092 478
Rendement du Dividende
2.08%
Ratio Cours sur Bénéfices
59,30
Bénéfice par action (BPA)
1,92
Chiffre d'affairess
45,81B
Bénéfice net
5,96B

À propos de AstraZeneca PLC

AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put s... AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive open and collaborative. This approach runs through all that we do. We focus on three main therapy areas Oncology Cardiovascular & Metabolic Disease CVMD and Respiratory and we are also selectively active in the areas of autoimmunity neuroscience and infection. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Cambridge, Gbr
Fondé
-
AstraZeneca PLC est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker AZN. Le dernier cours de clôture d'AstraZeneca était de US$71,24. Au cours de la dernière année, les actions de AstraZeneca ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

AstraZeneca compte actuellement 3 101 092 478 actions en circulation. La capitalisation boursière d'AstraZeneca est de US$220,92 milliard. AstraZeneca a un ratio cours/bénéfice (ratio PE) de 59.30.

Flux d'options AstraZeneca (AZN)

Flux global

Haussier

Prime nette

1M

Calls / Puts

137,50%

Ach. / Vent.

90,00%

OTM / ITM

58,33%

Sweeps Ratio

0,00%

AZN Dernières nouvelles

AZN LAWSUIT ALERT: The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline

AZN LAWSUIT ALERT: The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire NEW YORK, Jan. 30, 2025 NEW YORK, Jan. 30, 2025 /PRNewswire/...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

Based on DESTINY-Breast06 Phase III trial results which showed ENHERTU demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings...

Shareholders of AstraZeneca PLC Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZN

Shareholders of AstraZeneca PLC Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZN PR Newswire NEW YORK, Jan. 27, 2025 NEW YORK, Jan. 27, 2025 /PRNewswire/...

AstraZeneca PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZN

AstraZeneca PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZN PR Newswire NEW YORK, Jan. 23, 2025 NEW YORK, Jan. 23, 2025...

AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZN

AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZN PR Newswire LOS ANGELES, Jan. 23, 2025 LOS ANGELES, Jan. 23, 2025 /PRNewswire/ -- The...

The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN

The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN PR Newswire NEW YORK, Jan. 20, 2025 NEW YORK , Jan. 20, 2025 /PRNewswire/ -- The Gross...

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

First approval in the US for AstraZeneca and Daiichi Sankyo’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy...

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone First and only BTK inhibitor approved for the 1st-line...

Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZN

Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZN PR Newswire NEW YORK, Jan. 16, 2025 NEW YORK, Jan. 16, 2025 /PRNewswire/...

Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

Application based on TROPION-Lung05 trial and supported by data from TROPION-Lung01 and TROPION-PanTumor01 trials Approval would mark the first for AstraZeneca and Daiichi Sankyo’s datopotamab...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

AZN - Frequently Asked Questions (FAQ)

What is the current AstraZeneca share price?
The current share price of AstraZeneca is US$ 70,0818
How many AstraZeneca shares are in issue?
AstraZeneca has 3 101 092 478 shares in issue
What is the market cap of AstraZeneca?
The market capitalisation of AstraZeneca is USD 220,92B
What is the 1 year trading range for AstraZeneca share price?
AstraZeneca has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of AstraZeneca?
The price to earnings ratio of AstraZeneca is 59,3
What is the cash to sales ratio of AstraZeneca?
The cash to sales ratio of AstraZeneca is 7,71
What is the reporting currency for AstraZeneca?
AstraZeneca reports financial results in USD
What is the latest annual turnover for AstraZeneca?
The latest annual turnover of AstraZeneca is USD 45,81B
What is the latest annual profit for AstraZeneca?
The latest annual profit of AstraZeneca is USD 5,96B
What is the registered address of AstraZeneca?
The registered address for AstraZeneca is 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE, CB2 0AA
What is the AstraZeneca website address?
The website address for AstraZeneca is www.astrazeneca.com
Which industry sector does AstraZeneca operate in?
AstraZeneca operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
TCTMTCTM Kids IT Education Inc
US$ 0,764
(321,87%)
729,72M
REBNReborn Coffee Inc
US$ 3,31
(63,05%)
55,54M
FCUVFocus Universal Inc
US$ 5,87
(56,62%)
1,73M
SOPASociety Pass Inc
US$ 1,54
(56,50%)
13,82M
CYCNCyclerion Therapeutics Inc
US$ 3,92
(54,33%)
82,39M
ENVBEnveric Biosciences Inc
US$ 2,0899
(-46,41%)
1,58M
NIVFNewGenIvf Group Ltd
US$ 0,1489
(-42,51%)
14,91M
GLSTGlobal Star Acquisition Inc
US$ 8,83
(-39,10%)
23,93k
PRPHProPhase Labs Inc
US$ 0,2633
(-38,02%)
900,48k
SPGCSacks Parente Golf Inc
US$ 0,5601
(-37,86%)
7,42M
TCTMTCTM Kids IT Education Inc
US$ 0,764
(321,87%)
729,72M
NVDANVIDIA Corporation
US$ 120,07
(-3,67%)
388,54M
RIMEAlgorhythm Holdings Inc
US$ 0,02565
(5,12%)
338,75M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0355
(-11,25%)
236,29M
CLEUChina Liberal Education Holdings Ltd
US$ 0,1938
(30,77%)
234,8M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock